Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Current Deferred Revenue (2022 - 2024)

Historic Current Deferred Revenue for Kiniksa Pharmaceuticals International (KNSA) over the last 3 years, with Q4 2024 value amounting to $31.8 million.

  • Kiniksa Pharmaceuticals International's Current Deferred Revenue rose 15944.87% to $31.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $31.8 million, marking a year-over-year increase of 15944.87%. This contributed to the annual value of $31.8 million for FY2024, which is 15944.87% up from last year.
  • Kiniksa Pharmaceuticals International's Current Deferred Revenue amounted to $31.8 million in Q4 2024, which was up 15944.87% from $12000.0 recorded in Q2 2024.
  • Kiniksa Pharmaceuticals International's 5-year Current Deferred Revenue high stood at $31.8 million for Q4 2024, and its period low was $12000.0 during Q2 2024.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Current Deferred Revenue had a median value of $5.6 million in 2023 and averaged $10.5 million.
  • Over the last 5 years, Kiniksa Pharmaceuticals International's Current Deferred Revenue had its largest YoY gain of 15944.87% in 2024, and its largest YoY loss of 9974.33% in 2024.
  • Quarter analysis of 3 years shows Kiniksa Pharmaceuticals International's Current Deferred Revenue stood at $26.3 million in 2022, then crashed by 53.36% to $12.3 million in 2023, then soared by 159.45% to $31.8 million in 2024.
  • Its last three reported values are $31.8 million in Q4 2024, $12000.0 for Q2 2024, and $156000.0 during Q1 2024.